Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphoma
Phase 2
Recruiting
- Conditions
- relapsed or refractory non-Hodgkin's lymphoma
- Registration Number
- JPRN-UMIN000015998
- Lead Sponsor
- Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients have CNS invasion. 2) HIV antibody positive. 3) Patients have interstitial pneumonia or pulmonary fibrosis evidenced by chest X-ray and/or chest CT. 4) Patients undergoing chest radiotherapy. 5) Patients have major heart/lung disorders, or uncontrolled diabetes mellitus. 6) Patients are pregnant or lactating women. Patients cannot or will not use birth control during the treatment. 7) Patients have active other malignant diseases. 8) Patients have severe allergic symptoms. 9) Patients have chemotherapy resistant lymphoma. 10) Inadequate for clinical trial entry by the attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complete response rate
- Secondary Outcome Measures
Name Time Method overall response rate overall survival progression free survival safety peripheral blood stem cell harvest (transplant case)